Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16,080 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term outcomes of second-line versus later-line zanubrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: An updated pooled analysis.
Song Y, Zhou K, Zou D, Li D, Hu J, Yang H, Zhang H, Ji J, Xu W, Jin J, Lv F, Feng R, Gao S, Zhou D, Tam CS, Simpson D, Wang M, Phillips TJ, Opat S, Fang C, Sun S, Zhu J. Song Y, et al. Among authors: gao s. Cancer Med. 2023 Sep;12(18):18643-18653. doi: 10.1002/cam4.6473. Epub 2023 Sep 14. Cancer Med. 2023. PMID: 37705497 Free PMC article.
Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study.
Xu W, Yang S, Zhou K, Pan L, Li Z, Zhou J, Gao S, Zhou D, Hu J, Feng R, Huang H, Ji M, Guo H, Huang J, Novotny W, Feng S, Li J. Xu W, et al. Among authors: gao s. J Hematol Oncol. 2020 May 11;13(1):48. doi: 10.1186/s13045-020-00884-4. J Hematol Oncol. 2020. PMID: 32393328 Free PMC article. Clinical Trial.
Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase.
Song Y, Zhou K, Zou D, Zhou J, Hu J, Yang H, Zhang H, Ji J, Xu W, Jin J, Lv F, Feng R, Gao S, Guo H, Zhou L, Elstrom R, Huang J, Novotny W, Wei R, Zhu J. Song Y, et al. Among authors: gao s. Clin Cancer Res. 2020 Aug 15;26(16):4216-4224. doi: 10.1158/1078-0432.CCR-19-3703. Epub 2020 May 27. Clin Cancer Res. 2020. PMID: 32461234 Clinical Trial.
YF-H-2015005, a CXCR4 Antagonist, for the Mobilization of Hematopoietic Stem Cells in Non-Hodgkin Lymphoma Patients: A Randomized, Controlled, Phase 3 Clinical Trial.
Liu W, Li Y, Wang Q, Su H, Ding K, Shuang Y, Gao S, Zou D, Jing H, Chai Y, Zhang Y, Liu L, Wang C, Liu H, Lin J, Zhu H, Yao C, Yan X, Shang M, Wang S, Chang F, Wang X, Zhu J, Song Y. Liu W, et al. Among authors: gao s. Front Med (Lausanne). 2021 Feb 2;8:609116. doi: 10.3389/fmed.2021.609116. eCollection 2021. Front Med (Lausanne). 2021. PMID: 33604348 Free PMC article.
A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia.
Mei H, Liu X, Li Y, Zhou H, Feng Y, Gao G, Cheng P, Huang R, Yang L, Hu J, Hou M, Yao Y, Liu L, Wang Y, Wu D, Zhang L, Zheng C, Shen X, Hu Q, Liu J, Jin J, Luo J, Zeng Y, Gao S, Zhang X, Zhou X, Shi Q, Xia R, Xie X, Jiang Z, Gao L, Bai Y, Li Y, Xiong J, Li R, Zou J, Niu T, Yang R, Hu Y. Mei H, et al. Among authors: gao s, gao g, gao l. J Hematol Oncol. 2021 Feb 25;14(1):37. doi: 10.1186/s13045-021-01047-9. J Hematol Oncol. 2021. PMID: 33632264 Free PMC article. Clinical Trial.
Real-world assessment of the effectiveness of posaconazole for the prophylaxis and treatment of invasive fungal infections in hematological patients: A retrospective observational study.
Chen X, Wang J, Wang S, Jin J, Li J, Gao S, Li J, Li J, Liu Q, Hu Y, Lin D, Sun Z, Yang J, Hu J, Wu X, Huang X, Shao Z, Deng Q, Wang C, Liu L, Chen H, Wang J, Wei X, Shen J, Zhang X, Wu D. Chen X, et al. Among authors: gao s. Medicine (Baltimore). 2021 Jul 30;100(30):e26772. doi: 10.1097/MD.0000000000026772. Medicine (Baltimore). 2021. PMID: 34397725 Free PMC article.
Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials.
Zhou K, Zou D, Zhou J, Hu J, Yang H, Zhang H, Ji J, Xu W, Jin J, Lv F, Feng R, Gao S, Zhou D, Tam CS, Simpson D, Wang M, Phillips TJ, Opat S, Huang Z, Lu H, Song Y, Song Y. Zhou K, et al. Among authors: gao s. J Hematol Oncol. 2021 Oct 14;14(1):167. doi: 10.1186/s13045-021-01174-3. J Hematol Oncol. 2021. PMID: 34649571 Free PMC article. Clinical Trial.
Dose tapering to withdrawal stage and long-term efficacy and safety of hetrombopag for the treatment of immune thrombocytopenia: Results from an open-label extension study.
Mei H, Liu X, Li Y, Zhou H, Feng Y, Gao G, Cheng P, Huang R, Yang L, Hu J, Hou M, Yao Y, Liu L, Wang Y, Wu D, Zhang L, Zheng C, Shen X, Hu Q, Liu J, Jin J, Luo J, Zeng Y, Gao S, Zhang X, Zhou X, Shi Q, Xia R, Xie X, Jiang Z, Gao L, Bai Y, Li Y, Xiong J, Li R, Zou J, Niu T, Yang R, Hu Y. Mei H, et al. Among authors: gao s, gao g, gao l. J Thromb Haemost. 2022 Mar;20(3):716-728. doi: 10.1111/jth.15602. Epub 2021 Dec 15. J Thromb Haemost. 2022. PMID: 34821020 Free article. Clinical Trial.
Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study.
Qiu L, Xia Z, Fu C, Chen W, Chang C, Fang B, An G, Wei Y, Cai Z, Gao S, Weng J, Chen L, Jing H, Li F, Liu Z, Chen X, Liu J, Wang A, Yu Y, Xiang W, Lynch K, Yu Z, Fu W. Qiu L, et al. Among authors: gao s. BMC Med. 2022 Apr 5;20(1):108. doi: 10.1186/s12916-022-02305-4. BMC Med. 2022. PMID: 35379237 Free PMC article. Clinical Trial.
16,080 results
You have reached the last available page of results. Please see the User Guide for more information.